Ali Ekin

Bursa, Turkey

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

A clinically contextualized, hands-on biostatistics workshop for rheumatology fellows-in-training: a quasi-experimental pre-post educational intervention study.

A clinically contextualized, hands-on biostatistics workshop for rheumatology fellows-in-training: a quasi-experimental pre-post educational intervention study.

Journal: BMC medical education

Published: April 26, 2026

The Effect of Adding Paraffin Bath to the Therapeutic Hand Exercise Programme on Hand Functions in Patients with Systemic Sclerosis: A Randomized, Controlled, Single-Blind Study.

The Effect of Adding Paraffin Bath to the Therapeutic Hand Exercise Programme on Hand Functions in Patients with Systemic Sclerosis: A Randomized, Controlled, Single-Blind Study.

Journal: Archives of rheumatology

Published: February 23, 2026

Clinical spectrum and outcomes of mononeuritis multiplex in rheumatic diseases: evidence from a nationwide multicenter study.

Clinical spectrum and outcomes of mononeuritis multiplex in rheumatic diseases: evidence from a nationwide multicenter study.

Journal: Therapeutic advances in musculoskeletal disease

Published: January 20, 2026

Does the Use of Denosumab in Combination with bDMARDs or tsDMARDs Increase the Risk of Infection in Patients with Osteoporosis and Inflammatory Rheumatic Diseases?

Does the Use of Denosumab in Combination with bDMARDs or tsDMARDs Increase the Risk of Infection in Patients with Osteoporosis and Inflammatory Rheumatic Diseases?

Journal: Journal of clinical medicine

Published: July 14, 2025

Patients Diagnosed with Granulomatosis with Polyangiitis: The Journey to Receive Rheumatologist Care.

Patients Diagnosed with Granulomatosis with Polyangiitis: The Journey to Receive Rheumatologist Care.

Journal: Journal of clinical medicine

Published: April 15, 2025

Treatment with nintedanib is as effective and safe in patients with other connective tissue diseases (CTDs)-interstitial lung disease (ILD) as in patients with systemic sclerosis-ILD: A multicenter retrospective study.

Treatment with nintedanib is as effective and safe in patients with other connective tissue diseases (CTDs)-interstitial lung disease (ILD) as in patients with systemic sclerosis-ILD: A multicenter retrospective study.

Journal: Clinical rheumatology

Published: December 03, 2024

Rheumatologic Perspectives on Sarcoidosis: Predicting Sarcoidosis-Associated Arthritis Through Comprehensive Clinical and Laboratory Assessment.

Rheumatologic Perspectives on Sarcoidosis: Predicting Sarcoidosis-Associated Arthritis Through Comprehensive Clinical and Laboratory Assessment.

Journal: Journal of clinical medicine

Published: November 13, 2024

Does the LDH/Albumin Ratio Bring Novelty? A Comparative Analysis with Inflammatory Indices and Combined Models in Adult-Onset Still's Disease.

Does the LDH/Albumin Ratio Bring Novelty? A Comparative Analysis with Inflammatory Indices and Combined Models in Adult-Onset Still's Disease.

Journal: Diagnostics (Basel, Switzerland)

Published: November 12, 2024

Idiopathic granulomatous mastitis: TNFi effectivity in a retrospective inception cohort.

Idiopathic granulomatous mastitis: TNFi effectivity in a retrospective inception cohort.

Journal: Clinical rheumatology

Published: September 18, 2024

Efficacy and safety of tofacitinib in rheumatoid arthritis: Nine years of real-world data.

Efficacy and safety of tofacitinib in rheumatoid arthritis: Nine years of real-world data.

Journal: Clinical and translational science

Published: August 05, 2024

The Validation of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria in a Cohort from Turkey.

The Validation of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria in a Cohort from Turkey.

Journal: Diagnostics (Basel, Switzerland)

Published: July 26, 2024

The retrospective evaluation of efficacy and safety data after switching from originator rituximab to biosimilar rituximab (CT-P10) in patients diagnosed with systemic lupus erythematosus: a single-center experience.

The retrospective evaluation of efficacy and safety data after switching from originator rituximab to biosimilar rituximab (CT-P10) in patients diagnosed with systemic lupus erythematosus: a single-center experience.

Journal: European review for medical and pharmacological sciences

Published: June 10, 2024

Showing 1-12 of 15

Last Updated: 09/26/2026